001     120596
005     20240228145455.0
024 7 _ |a 10.1007/s00259-016-3594-z
|2 doi
024 7 _ |a pmid:27988802
|2 pmid
024 7 _ |a 0340-6997
|2 ISSN
024 7 _ |a 1432-105X
|2 ISSN
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a altmetric:17885527
|2 altmetric
037 _ _ |a DKFZ-2017-01024
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Freitag, Martin
|0 P:(DE-He78)c420f6efccb409e1a287be027501a74c
|b 0
|e First author
245 _ _ |a Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.
260 _ _ |a Heidelberg [u.a.]
|c 2017
|b Springer-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660815008_8349
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The positron emission tomography (PET) tracer (68)Ga-PSMA-11, targeting the prostate-specific membrane antigen (PSMA), is rapidly excreted into the urinary tract. This leads to significant radioactivity in the bladder, which may limit the PET-detection of local recurrence (LR) of prostate cancer (PC) after radical prostatectomy (RP), developing in close proximity to the bladder. Here, we analyze if there is additional value of multi-parametric magnetic resonance imaging (mpMRI) compared to the (68)Ga-PSMA-11-PET-component of PET/CT or PET/MRI to detect LR.One hundred and nineteen patients with biochemical recurrence after prior RP underwent both hybrid (68)Ga-PSMA-11-PET/CTlow-dose (1 h p.i.) and -PET/MRI (2-3 h p.i.) including a mpMRI protocol of the prostatic bed. The comparison of both methods was restricted to the abdomen with focus on LR (McNemar). Bladder-LR distance and recurrence size were measured in axial T2w-TSE. A logistic regression was performed to determine the influence of these variables on detectability in (68)Ga-PSMA-11-PET. Standardized-uptake-value (SUVmean) quantification of LR was performed.There were 93/119 patients that had at least one pathologic finding. In addition, 18/119 Patients (15.1%) were diagnosed with a LR in mpMRI of PET/MRI but only nine were PET-positive in PET/CT and PET/MRI. This mismatch was statistically significant (p = 0.004). Detection of LR using the PET-component was significantly influenced by proximity to the bladder (p = 0.028). The PET-pattern of LR-uptake was classified into three types (1): separated from bladder; (2): fuses with bladder, and (3): obliterated by bladder). The size of LRs did not affect PET-detectability (p = 0.84), mean size was 1.7 ± 0.69 cm long axis, 1.2 ± 0.46 cm short-axis. SUVmean in nine men was 8.7 ± 3.7 (PET/CT) and 7.0 ± 4.2 (PET/MRI) but could not be quantified in the remaining nine cases (obliterated by bladder).The present study demonstrates additional value of hybrid (68)Ga-PSMA-11-PET/MRI by gaining complementary diagnostic information compared to (the 68)Ga-PSMA-11-PET/CTlow-dose for patients with LR of PC.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a (68Ga)Glu-urea-Lys(Ahx)-HBED-CC
|2 NLM Chemicals
650 _ 7 |a Organometallic Compounds
|2 NLM Chemicals
700 1 _ |a Radtke, Jan Philipp
|0 P:(DE-He78)79897f8897ff77676549d9895258a0f2
|b 1
700 1 _ |a Afshar-Oromieh, Ali
|0 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c
|b 2
700 1 _ |a Roethke, Matthias C
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Hadaschik, Boris A
|b 4
700 1 _ |a Gleave, Martin
|b 5
700 1 _ |a Bonekamp, David
|0 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
|b 6
700 1 _ |a Kopka, Klaus
|0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
|b 7
700 1 _ |a Eder, Matthias
|0 P:(DE-He78)331382460d902d1341dc73db8b990f97
|b 8
700 1 _ |a Heusser, Thorsten
|0 P:(DE-He78)a00a109668c5fdbeea213d6981588250
|b 9
|u dkfz
700 1 _ |a Kachelriess, Marc
|0 P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323
|b 10
700 1 _ |a Wieczorek, Kathrin
|b 11
700 1 _ |a Sachpekidis, Christos
|0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|b 12
700 1 _ |a Flechsig, Paul
|b 13
700 1 _ |a Giesel, Frederik
|0 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94
|b 14
700 1 _ |a Hohenfellner, Markus
|b 15
700 1 _ |a Haberkorn, Uwe
|0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
|b 16
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 17
700 1 _ |a Dimitrakopoulou-Strauss, A.
|0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|b 18
|e Last author
773 _ _ |a 10.1007/s00259-016-3594-z
|g Vol. 44, no. 5, p. 776 - 787
|0 PERI:(DE-600)2098375-X
|n 5
|p 776 - 787
|t European journal of nuclear medicine and molecular imaging
|v 44
|y 2017
|x 1619-7089
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120596
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)c420f6efccb409e1a287be027501a74c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)79897f8897ff77676549d9895258a0f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)331382460d902d1341dc73db8b990f97
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)a00a109668c5fdbeea213d6981588250
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)f288a8f92f092ddb41d52b1aeb915323
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NUCL MED MOL I : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NUCL MED MOL I : 2015
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 1
920 1 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 2
920 1 _ |0 I:(DE-He78)E020-20160331
|k E020
|l E020 Med. Physik in der Radiologie
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)E030-20160331
980 _ _ |a I:(DE-He78)E020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21